Cargando…

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users

Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended-release oxycodone hydrochloride surrounding sequestered naltrexone hydrochloride. Design. Randomized, double-blind, placebo-/active-controlled, 6-way crossover study, with naloxone cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Setnik, Beatrice, Bass, Almasa, Bramson, Candace, Levy-Cooperman, Naama, Malhotra, Bimal, Matschke, Kyle, Geoffroy, Pierre, Sommerville, Kenneth W., Wolfram, Gernot
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914361/ https://www.ncbi.nlm.nih.gov/pubmed/27550954 http://dx.doi.org/10.1093/pm/pnw178

Ejemplares similares

A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
por: Webster, Lynn R., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users
por: Smith, Michael D., et al.
Publicado: (2017)

Diversion and Illicit Sale of Extended Release Tapentadol in the United States
por: Dart, Richard C., et al.
Publicado: (2016)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)
por: Kopecky, Ernest A., et al.
Publicado: (2016)

Consensus Recommendations on Initiating Prescription Therapies for Opioid‐Induced Constipation
por: Argoff, Charles E., et al.
Publicado: (2015)

ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes
por: Cepeda, M. Soledad, et al.
Publicado: (2017)

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
por: Webster, Lynn, et al.
Publicado: (2016)

One Month of Oral Morphine Decreases Gray Matter Volume in the Right Amygdala of Individuals with Low Back Pain: Confirmation of Previously Reported Magnetic Resonance Imaging Results
por: Lin, Joanne C., et al.
Publicado: (2016)

Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
por: Webster, Lynn, et al.
Publicado: (2018)

Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study
por: Bass, Almasa, et al.
Publicado: (2019)

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation
por: Webster, Lynn R, et al.
Publicado: (2019)

A retrospective chart review of opioid represcribing following nonfatal overdose at a Veterans Affairs hospital
por: Boyle, Julia, et al.
Publicado: (2018)

Implementation and results of a symptom-triggered opioid withdrawal protocol at a Veterans Affairs medical center
por: Koch, Jessa, et al.
Publicado: (2018)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain
por: Weil, Arnold J., et al.
Publicado: (2017)

Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2017)

Nicotine Gateway Effects on Adolescent Substance Use
por: Ren, Michelle, et al.
Publicado: (2019)

Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
por: Harris, Stephen C, et al.
Publicado: (2014)

Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users
por: Webster, Lynn R, et al.
Publicado: (2012)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia
por: Lam, Tina, et al.
Publicado: (2022)

A qualitative investigation of the role of the family in structuring young people’s alcohol use
por: Jacob, Nina, et al.
Publicado: (2016)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy
por: Black, Joshua C, et al.
Publicado: (2020)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients
por: Lauretti, G R, et al.
Publicado: (2003)

Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
por: Pergolizzi, Joseph V, et al.
Publicado: (2018)

Trends and uptake of new formulations of controlled‐release oxycodone in Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users
por: Webster, Lynn R., et al.
Publicado: (2012)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users
por: Raofi, Saeid, et al.
Publicado: (2021)

Reward-Related Attentional Capture Is Associated With Severity of Addictive and Obsessive–Compulsive Behaviors
por: Albertella, Lucy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d4o8d7t47m2fuu6ghnsfp97870